Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Item

http://www.wikidata.org/entity/Q33582914

Q33582914

about

Targeted therapies in sarcomas: challenging the challenge Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma MicroRNAs and Potential Targets in Osteosarcoma: Review Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers The study of a novel sorafenib derivative HLC-080 as an antitumor agent Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.miR-155 inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Emerging therapeutic targets for synovial sarcoma.ß1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion Sorafenib exerts anti-glioma activity in vitro and in vivo.Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.Lung cells support osteosarcoma cell migration and survival.Broad targeting of resistance to apoptosis in cancer.Future directions in the treatment of osteosarcoma.The T-box transcription factor 3 is a promising biomarker and a key regulator of the oncogenic phenotype of a diverse range of sarcoma subtypes Past, present and future of therapies in pediatric sarcomas.Emerging drugs for high-grade osteosarcoma.Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.Orthopaedic research in italy: state of the art.The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.Targeted therapy in bone and soft tissue sarcoma in children and adolescents.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.Targeted therapies for bone sarcomas.Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.Advances in emerging drugs for osteosarcoma.A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma.An update on chemotherapy for osteosarcoma.Metastatic osteosarcoma: a challenging multidisciplinary treatment.

P2860

Q21285014-3140CEA2-0340-42CE-8892-09BBCA727E06 Q26750631-50C64325-46D2-4332-B17E-B511ECF09F2A Q26784033-E6D69815-7274-4F2C-AAC5-49BF78BB333B Q26829949-13D42764-BECF-4F91-BBA1-76A9BF2238C9 Q28082793-C7E26D25-0FBE-4839-BFCE-E85080C82052 Q28540521-8E444C44-CF6D-4136-814A-41D73F6AB50D Q30560102-9F526E76-5DB6-4B53-88EA-E26F3876EB1F Q31018689-FF605AF1-9B96-4A70-92A1-DCEC398FCACD Q33408668-62918BD9-5485-45E7-8A2F-AE40B326FD53 Q33735680-7A80480C-A487-485A-9F5C-3D4AA0D915ED Q34094154-DC262D4E-BF8C-4643-9246-347B9D0267CC Q34116434-688DAA97-C8F6-4C87-A501-56B1D4960F36 Q34241371-0A3DC034-A0F8-4B1B-948D-8018B43EA77B Q34292411-7A7936DF-4A9E-49AC-A83B-145A5A55F1CE Q34619815-58AB4A38-02BE-4F96-B0B7-FC8521E200F1 Q34628840-72B80EE3-D4F5-46CD-BCE7-71A94A489179 Q34660607-820038AA-260E-485C-82FC-164532240659 Q35005380-BE7FD819-2C1D-42C1-9C86-3E766FB8A843 Q35414966-56016372-D2CB-4988-B867-DBE5453EE9A8 Q35552532-57988ED1-16FA-41DE-ADC8-30413BB35F85 Q35599789-C6C2791B-5913-4AE8-8637-3035D840D8DC Q36124088-BABDDB0B-C213-403C-8E6F-CE01D4E65CB2 Q36260257-92761AB8-14E3-43D6-9184-3F106B8E1B7F Q36483749-9D50DF95-76CC-401F-9F3C-179C6FFDCB8D Q36600800-66944A40-460E-4804-A3AA-D13A7F7B131E Q37499273-6CF4FC72-5BD1-420B-9D79-370F1CB6BA7F Q37725915-C19A0FE0-B0EB-4A74-A080-AB5BC0B87C20 Q37778400-CB526B33-2E3A-49DE-9220-FB2467F1AA80 Q37860966-9199E17C-B640-4190-9E6B-B1BF598FF3F9 Q37888852-E9B90375-62C8-4A60-BB68-94AB338B6385 Q37978530-89152259-67F0-4381-A029-BDC797B97535 Q37981129-3C7C7E5C-0561-4E6D-B27D-8435F97B6890 Q38120777-DAEAFBE6-E51B-4331-87F1-53CB2D19C92D Q38137804-563CEE92-2BAC-479E-B64D-47FC68ACD35B Q38178277-78AEBACB-915E-4D27-99CB-DC8B386E8860 Q38349935-105C59BD-0B4C-4FEA-8139-C9837046FC27 Q38506118-CD54B556-9FDF-4BC9-A416-9BA562F6BA38 Q38614928-B1A46971-4AEF-46CC-B32A-A2FEFB2E6326 Q38619114-89CCAAF5-471A-4061-AC2F-1B66BB9FBBA0 Q38783252-0107BD60-BAEC-45F2-8AD1-D259B5512562

P2860

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Item

http://www.wikidata.org/entity/Q33582914

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu